Claim and evidence Close ×
Exscientia's IPO prospectus (30 September 2021) states that it began a Phase 1 clinical trial of its internally developed candidate EXS21546 in December 2020, and that two other candidates, developed by Sumitomo Dainippon Pharma, were in Phase 1 trials. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source; Context: primary · 1 source
Provision Statement · provision ID co-exscientia-phase1-2021 Date 2021-09-30 · publication Records dated 2021 → Scope and limits The company's statement in an offering document, not a registry record. Exscientia calls these "the first three AI-designed precision drug candidates to enter human clinical trials"; that ordinal claim is the company's and is recorded as context, not as fact.
The evidence 03 primary source Supports the claim
Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares ↗ Exscientia plc (filed with the US SEC) · 2021-09-30
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “Among these is our most advanced internally developed drug candidate, EXS21546. We began the first Phase 1 clinical trial of this drug candidate in December 2020” Location in source Prospectus summary, "Demonstrating the Impact of our AI" (same sentences in Business, Overview)
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Exscientia plc (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 4b5b5bf7d5e80cc8f35a5daeaf2c39ac6a9c04508d08ca692aaccda878c03973). SEC EDGAR 424B4, accession 0001104659-21-122290; prospectus dated September 30, 2021; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Exscientia plc (filed with the US SEC), “Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares”, 2021-09-30. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (26 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Supports the claim
Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares ↗ Exscientia plc (filed with the US SEC) · 2021-09-30
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “The other two drug candidates, also currently in Phase 1 clinical trials, are being developed by our collaboration partner, Sumitomo Dainippon Pharma Co., Ltd.” Location in source Prospectus summary, "Demonstrating the Impact of our AI" (same sentences in Business, Overview)
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Exscientia plc (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 4b5b5bf7d5e80cc8f35a5daeaf2c39ac6a9c04508d08ca692aaccda878c03973). SEC EDGAR 424B4, accession 0001104659-21-122290; prospectus dated September 30, 2021; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Exscientia plc (filed with the US SEC), “Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares”, 2021-09-30. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (24 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Context only
Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares ↗ Exscientia plc (filed with the US SEC) · 2021-09-30
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “We originated the first three AI-designed precision drug candidates to enter human clinical trials.” Location in source Prospectus summary, "Demonstrating the Impact of our AI" (same sentences in Business, Overview)
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Exscientia plc (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 4b5b5bf7d5e80cc8f35a5daeaf2c39ac6a9c04508d08ca692aaccda878c03973). SEC EDGAR 424B4, accession 0001104659-21-122290; prospectus dated September 30, 2021; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Exscientia plc (filed with the US SEC), “Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares”, 2021-09-30. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (14 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. The company's priority claim, quoted and attributed; not adopted. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.
Date. Dated by the prospectus; the trial start month (December 2020) is the company's statement within it.
Record ID aib-co-exscientia-phase1-2021